KROS
Income statement / Annual
Last year (2023), Keros Therapeutics, Inc.'s total revenue was $151,000.00,
and the percentage change from the previous year is not available.
In 2023, Keros Therapeutics, Inc.'s net income was -$152.99 M.
See Keros Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$151,000.00
|
$0.00
|
$20.10 M
|
$0.00
|
$10.00 M
|
$10.00 M
|
| Cost of Revenue |
$815,000.00 |
$1.62 M |
$898,000.00 |
$605,000.00 |
$17.35 M |
$10.11 M |
| Gross Profit |
-$664,000.00 |
-$1.62 M |
$19.20 M |
-$605,000.00 |
-$7.35 M |
-$111,000.00 |
| Gross Profit Ratio |
-4.4 |
0 |
0.96 |
0 |
-0.73 |
-0.01 |
| Research and Development
Expenses |
$135.26 M
|
$87.27 M
|
$55.14 M
|
$33.86 M
|
$17.38 M
|
$10.11 M
|
| General & Administrative
Expenses |
$34.83 M
|
$27.53 M
|
$21.33 M
|
$12.80 M
|
$3.18 M
|
$1.58 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$34.83 M
|
$27.53 M
|
$21.33 M
|
$12.80 M
|
$3.18 M
|
$1.58 M
|
| Other Expenses |
$0.00 |
-$7.08 M |
-$356,000.00 |
-$2.46 M |
-$558,000.00 |
$237,000.00 |
| Operating Expenses |
$170.09 M |
$107.71 M |
$76.47 M |
$44.20 M |
$20.01 M |
$11.32 M |
| Cost And Expenses |
$170.09 M |
$107.71 M |
$76.47 M |
$44.20 M |
$20.01 M |
$11.32 M |
| Interest Income |
$0.00 |
$1,000.00 |
$4,000.00 |
$6,000.00 |
$8,000.00 |
$6,000.00 |
| Interest Expense |
$0.00 |
$1,000.00 |
$4,000.00 |
$6,000.00 |
$8,000.00 |
$0.00 |
| Depreciation &
Amortization |
$815,000.00
|
$1.62 M
|
$898,000.00
|
$605,000.00
|
$438,000.00
|
$304,000.00
|
| EBITDA |
-$152.18 M
|
-$103.06 M
|
-$56.37 M
|
-$44.92 M
|
-$11.89 M
|
-$774,000.00
|
| EBITDA Ratio |
-1007.79 |
0 |
-2.82 |
0 |
-0.98 |
-0.12 |
| Operating Income Ratio
|
-1125.44
|
0
|
-2.8
|
0
|
-1.06
|
-0.17
|
| Total Other
Income/Expenses Net |
$16.95 M
|
$10.11 M
|
-$360,000.00
|
$1.12 M
|
-$1.77 M
|
$613,000.00
|
| Income Before Tax |
-$152.99 M |
-$104.68 M |
-$56.73 M |
-$45.53 M |
-$12.34 M |
-$1.08 M |
| Income Before Tax Ratio
|
-1013.19
|
0
|
-2.82
|
0
|
-1.23
|
-0.11
|
| Income Tax Expense |
$0.00 |
$1,000.00 |
$2.01 M |
-$172,000.00 |
$8,000.00 |
$257,000.00 |
| Net Income |
-$152.99 M |
-$104.68 M |
-$58.74 M |
-$45.36 M |
-$12.34 M |
-$1.34 M |
| Net Income Ratio |
-1013.19 |
0 |
-2.92 |
0 |
-1.23 |
-0.13 |
| EPS |
-5.2 |
-4.15 |
-2.52 |
-2.93 |
-1.39 |
-0.15 |
| EPS Diluted |
-5.2 |
-4.15 |
-2.52 |
-2.93 |
-1.39 |
-0.15 |
| Weighted Average Shares
Out |
$29.45 M
|
$25.24 M
|
$23.33 M
|
$15.51 M
|
$8.88 M
|
$8.88 M
|
| Weighted Average Shares
Out Diluted |
$29.45 M
|
$25.24 M
|
$23.33 M
|
$15.51 M
|
$8.88 M
|
$8.88 M
|
| Link |
|
|
|
|
|
|
